Clinical Trial Update: Efficacy and Safety of ICS/LABA vs. LAMA/LABA in Patients With Different COPD Phenotypes. [Phase 4]

View source ↗

Summary

A Phase 4 trial comparing ICS/LABA versus LAMA/LABA in COPD patients to assess efficacy and safety across different COPD phenotypes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• ICS+LABA (inhaled corticosteroid + long-acting beta-agonist)
• LAMA+LABA (LAMA+LABA)

Snippet

Sponsor: National Institute of Respiratory Diseases, Mexico | Conditions: COPD | Phase 4 | Status: COMPLETED